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ABSTRACT
Objectives To assess the cost- effectiveness of universal 
repeat screening for syphilis in late pregnancy, compared 
with the current strategy of single screening in early 
pregnancy with repeat screening offered only to high- risk 
women.
Design A decision tree model was developed to assess 
the incremental costs and health benefits of the two 
screening strategies. The base case analysis considered 
short- term costs during the pregnancy and the initial 
weeks after delivery. Deterministic and probabilistic 
sensitivity analyses and scenario analyses were conducted 
to assess the robustness of the results.
Setting UK antenatal screening programme.
Population Hypothetical cohort of pregnant women who 
access antenatal care and receive a syphilis screen in 1 year.
Primary and secondary outcome measures The 
primary outcome was the cost to avoid one case of 
congenital syphilis (CS). Secondary outcomes were the 
cost to avoid one case of intrauterine fetal demise (IUFD) 
or neonatal death and the number of women needing to be 
screened/treated to avoid one case of CS, IUFD or neonatal 
death. The cost per quality- adjusted life year gained was 
assessed in scenario analyses.
Results Base case results indicated that for pregnant 
women in the UK (n=725 891), the repeat screening 
strategy would result in 5.5 fewer cases of CS (from 8.8 
to 3.3), 0.1 fewer cases of neonatal death and 0.3 fewer 
cases of IUFD annually compared with the single screening 
strategy. This equates to an additional £1.8 million 
per case of CS prevented. When lifetime horizon was 
considered, the incremental cost- effectiveness ratio for the 
repeat screening strategy was £120 494.
Conclusions Universal repeat screening for syphilis in 
pregnancy is unlikely to be cost- effective in the current UK 
setting where syphilis prevalence is low. Repeat screening may 
be cost- effective in countries with a higher syphilis incidence in 
pregnancy, particularly if the cost per screen is low.
INTRODUCTION
Syphilis is a bacterial sexually transmitted 
infection (STI) caused by Treponema pallidum 
subspecies pallidum. The prevalence of syph-
ilis in the UK is low, however, the number 
of new diagnoses has increased over the last 
decade. In women, the number of cases rose 
from 345 in 2009 to 550 in 2018.1
Congenital syphilis (CS) occurs via vertical 
transmission of syphilis during the pregnancy 
which can occur during any trimester and at 
any of the four stages of syphilis infection. 
The highest risk of transmission, however, 
occurs in primary syphilis when sores or 
chancres are present. Adverse pregnancy 
outcomes can include intrauterine fetal 
demise (IUFD), prematurity and neonatal 
death, with the risk being considerably 
higher in women with untreated syphilis 
than in pregnant women with no syphilis or 
in pregnant women who receive adequate 
treatment for syphilis following diagnosis at 
first trimester screening.2 The risk of CS is 
difficult to quantify due to the small number 
of cases, the wide range of disease presenta-
tions and probable underdiagnosis. There is 
evidence, although limited, that the risk of 
CS is higher if women become infected while 
pregnant than if they have active syphilis at 
Strengths and limitations of this study
 ► This is the first health economic analysis to assess 
the cost- effectiveness of a repeat screening strate-
gy for syphilis in pregnancy compared with a single 
screen strategy within the UK setting.
 ► Experts provided input to inform the model pa-
rameters and validate the model structure and 
assumptions.
 ► Extensive sensitivity analyses were performed to as-
sess uncertainty in the results.
 ► A lack of long- term data on the costs and utilities as-
sociated with congenital syphilis meant the focus of 
the analysis was on the short- term costs and health 
benefits, with the incremental cost- effectiveness ra-
tio being calculated in scenario analyses.
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the time of conception.2 3 In infants born with CS, the 
infection can cause reduced growth and development, 
neurological impairment, bone deformities and hearing 
loss.4 5 Infants treated with intravenous benzylpenicillin 
sodium in the first 2 months of life are reported to have a 
good short- term prognosis, but long- term outcomes have 
not been investigated in detail.6 7
In the UK, routine antenatal screening for syphilis, 
hepatitis B and HIV is offered to all pregnant women 
at their first routine antenatal appointment, usually 
before 12 weeks gestation, or later, for the small propor-
tion of women who first present in their second or third 
trimester.8 9 Women who decline screening are formally 
reoffered and screening coverage currently exceeds 
99.6%.9–11 Blood samples are initially tested using an 
enzyme immunoassay (EIA) with a T. pallidum particle 
agglutination assay (TPPA) performed on the same spec-
imen to confirm a positive result. Women with a posi-
tive TPPA result are referred to a sexual health clinic 
to assess whether they have an active infection which 
requires treatment or a previous infection not requiring 
treatment. It is possible that women who screen negative 
for syphilis become positive later in pregnancy, either 
because they become infected with syphilis, or because 
their infection was too recent for a detectable antibody 
response to have been mounted at the time of the first 
screen. Management guidelines, outside the national 
screening programme, recommend that women are 
offered repeat testing for syphilis in late pregnancy if they 
have been diagnosed and treated for syphilis in the first 
trimester, if they consider themselves to be at risk of infec-
tion, or have a single ‘high- risk’ exposure.11 12 Assessing 
women’s risk can be problematic and risk can change 
during pregnancy. Data on coverage of repeat testing or 
management is not routinely collected. In 2011–2013, the 
Surveillance of Antenatal Syphilis Screening (SASS) study 
was conducted to provide quantitative data on the perfor-
mance of the screening pathway.13
Syphilis prevalence in pregnant women is low, the SASS 
study found that 0.04% (1/2800) of pregnant women 
required treatment for syphilis in 2010–2011, although 
the prevalence may have subsequently increased.13 CS 
incidence is also low and below the WHO elimination 
threshold of ≤0.5/1000.14 However, between March 2016 
and January 2017, four cases of CS occurred in the UK 
in women who screened negative for syphilis in preg-
nancy.15 None of whom had a repeat screen during preg-
nancy, and confirmatory testing later showed that they 
had acquired syphilis while pregnant. These infections 
would likely have been diagnosed and treated if repeat 
screening in late pregnancy was offered to all preg-
nant women, an approach that has not been assessed 
in the UK. Two models assessed the cost- effectiveness of 
universal repeat screening in the USA, where the preva-
lence of syphilis in pregnant women is higher than in the 
UK. One found that universal repeat screening was cost 
saving,16 while the other found that it cost US$419 842 
per CS case avoided.17
To inform the UK National Screening Committee (UK 
NSC) and in response to an increase in syphilis diagnoses 
in the UK and the continued occurrence of CS cases each 
year, although very small numbers, the clinical and cost- 
effectiveness of universal screening in the first and third 
trimesters, as an alternative strategy to universal screening 
in the first trimester only, was assessed.
METHODS
Model structure
A decision tree model in TreeAge (TreeAge Pro 2019, 
R2. TreeAge Software, Williamstown, Massachusetts, 
USA) was developed to assess the incremental costs and 
health benefits of universal repeat screening for ante-
natal syphilis compared with universal screening in the 
first trimester only (figure 1). For both screening strate-
gies, the decision tree followed the true disease state of 
women and the population was split into women screened 
in the first/second trimester and women screened in the 
third trimester (ie, late presenters who would miss the 
opportunity for repeat screening). Women with a posi-
tive result received treatment at a sexual health clinic 
plus any additional testing required. Each branch (with 
or without syphilis) ended with the same pregnancy 
outcomes: IUFD or no IUFD, the latter resulting in a 
preterm or term delivery and either neonatal death, an 
infant with CS, or an infant with no CS (online supple-
mental figure S1).
The model included pregnant women in the UK who 
accessed antenatal care and received a syphilis screen 
in 2018 (the latest available data at the time). Pregnant 
women who were not screened (0.04%) were not included, 
since any change to the screening strategy would have no 
impact on their outcomes. Costs were considered from 
the UK healthcare system perspective. Social care costs 
were not included in the short term. To assess the overall 
impact of the two screening strategies, the costs for all 
pregnancy outcomes for all women screened were consid-
ered, not just costs for women with syphilis. The model 
threshold for early versus late first screen was 28 weeks 
gestation, that is, the start of the third trimester. The time 
horizon for the base case analysis considered short- term 
costs during the pregnancy and the perinatal period. Life-
time costs and utilities were not used in the base case anal-
ysis (but were considered in scenario analysis) as the data 
available on the long- term costs and utilities associated 
with CS were limited and include too much uncertainty 
to provide a robust result. See online supplemental table 
S1 for base case model assumptions.
Model parameters
Data were sought using PubMed, Google Scholar, online 
searches, references within papers, from experts and 
laboratory contacts and by data request to Public Health 
Agencies.
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Clinical parameters
Key clinical parameters were derived from published 
data and national surveillance data. Where data were 
only available from outside the UK, they were scaled to 
reflect UK pregnancy outcomes and syphilis prevalence. 
See table 1 for clinical parameters and methods of estima-
tion. Furthermore, data from a large meta- analysis18 were 
adjusted to the UK setting to estimate the probability of 
each pregnancy outcome (online supplemental tables 
S2–S5).
Cost parameters
Cost parameters are presented in table 1. National 
Health Service (NHS) tariff costs or published costs 
from the UK were used where possible. Where no UK 
data were available, microcosting was used to calculate 
costs—informed by clinical guidelines, expert opinion 
and incorporating published NHS costs and tariffs where 
possible. To estimate the additional lifetime cost of CS, 
cost estimates from outside the UK were converted to 
pound sterling (£).19 Where necessary, costs were 
Figure 1 Overview of decision tree comparing single screening with universal repeat screening of syphilis in pregnancy. With 
reference to the timing of 1st syphilis screen, ‘early’ refers to 1stor 2nd trimester and ‘late’ refers to the third trimester. Where 
branches split, the probabilities are shown in the top branch, with # indicating (1- probability). Blue circle indicates referral to 
specialist management for treatment and the same seven pregnancy outcomes (as is shown in the top branch). Each branch 
ends with the same outcomes, but with different probabilities for each branch. Pregnancy outcomes are presented in online 
supplemental figure S1. FN, false negative result; FP, false positive result; PW, pregnant women; TN, true negative result; TP, 
true positive result.
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Table 1 Clinical and cost parameters for model comparing single screening with universal repeat screening of syphilis in 
pregnancy in the UK
Baseline 
value Low High Distribution Note
Clinical parameters   
Total number of women 
in model (representing 
1 year)
725 891 – – – Based on number of deliveries in the UK 
in 2017/2018 and the screening uptake. 
See online supplemental table S6.
Probability of having 
syphilis at the start of 
pregnancy
0.00035 0.00028 0.00042 Beta Data derived from 2011 SASS data13 
(England only (244/691,494)).
Assume same risk in other UK countries.
Probability of becoming 
infected with syphilis 
during pregnancy
0.000017 0.0000017 0.00012 Beta Incidence was estimated using 
published incidence and prevalence 
data from USA scaled to reflect UK 
prevalence.13 32
Probability of receiving 
syphilis screen before 
28 weeks gestation
0.947 0.936 0.984 Beta Estimate based on gestational week at 
first antenatal attendance. See online 
supplemental table S7. The low value is 
in line with results from SASS study.13 
The high value is in line with data from 
Northern Ireland which (from the UK 
countries) has the highest proportion of 
women attending before 28 weeks.
Probability of true 
positive result
0.995 0.984 1.00 Beta Based on the average test sensitivity of 
five EIA assays used in the UK. High and 
low values are based on best and worst 
test performance of assays used in the 
UK.28 29
Probability of false 
negative result‡
0.005 0.016 0.00 Beta Based on the average test sensitivity of 
five EIA assays used in the UK. High and 
low values are based on best and worst 
test performance of assays used in the 
UK.28 29
Probability of true 
negative result
0.998 0.999 0.99 Beta Based on average test specificity of five 
EIA assays (99.8%) used in the UK.
High and low are estimates.28 29
Probability of false 
positive result‡
0.002 0.001 0.01 Beta Based on average test specificity of five 
EIA assays (99.8%) used in the UK. High 
and low are estimates.28 29
Cost parameters (£)   
Syphilis screen 13.36 6.68 26.72 Gamma Estimated using microcosting. 
Screening is performed at the same 
time as other antenatal blood tests—
this would also be the case for repeat 
screening at 28 weeks gestation. See 
online supplemental table S8.
Management of women 
diagnosed with syphilis 
in pregnancy
314.09 251.27 376.91 Gamma Clinical management by sexual health 
clinician estimate based on London 
Integrated Sexual Health Tariff.33 See 
online supplemental table S9.
Intrauterine fetal 
demise (IUFD)*
4356.80 3485.44 5228.16 Gamma Estimate based on 2013/2014 published 
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inflated to 2017/2018 prices using mid- year conversion 
rates.20
Outcomes
The primary outcome was cost to avoid one case of CS. 
Secondary outcomes were: cost to avoid one case of IUFD 
or neonatal death; the number of women who need to be 
screened to avoid one case of CS, IUFD or neonatal death; 
and the number of women who need to be treated for syph-
ilis to avoid one case of CS, IUFD or neonatal death.
Sensitivity and scenario analyses
A univariate deterministic sensitivity analysis (DSA) was 
run for all probabilities and costs to determine which 
parameters had the greatest impact on the outcome of 
the model. This was done by selecting a high and low 
value for each input and generating outcomes. A proba-
bilistic sensitivity analysis (PSA) using Monte- Carlo simu-
lation (1000 iterations) was used to assess the robustness 
of the results and calculate 95% credibility intervals for 
each output using the mean and standard deviation. A 
beta distribution was used for clinical probability inputs, 
and a gamma distribution for cost inputs (table 1).
As well as the base case analysis, seven scenarios were 
assessed to observe how changes in model assumptions 
and certain parameters impacted the main outcomes:
1. Lifetime time horizon with incremental cost- 
effectiveness ratio (ICER) in terms of cost per quality- 
adjusted life year (QALY) as the main outcome.
Baseline 
value Low High Distribution Note
Preterm delivery 7100.37 5680.30 8520.45 Gamma Estimate based on UK costs for delivery 
at 32–33 weeks and 34–36 weeks 
gestation (inflated from 2010/2011 
costs).35 UK data on gestational age 
at delivery (online supplemental table 
S10) were then used to calculate the 
proportion of deliveries at 32–33 (28%) 
and 34–36 weeks (72%).
Term delivery (37+ 
weeks)
2034.62 1627.69 2441.54 Gamma Estimate based on published cost using 
inflated 2010/2011 UK data.35
Neonatal death† 5805.80 4644.64 6966.96 Gamma Estimated using cost of IUFD plus 
additional hospital costs. See online 
supplemental table S11.
CS testing and 
treatment
6607.68 5286.14 7929.21 Gamma Estimated using microcosting. See 
online supplemental tables S12 and 
S13.
CS neonatal screen 245.25 196.20 294.30 Gamma Screening test for neonates born to 
women treated for syphilis in pregnancy. 
Estimated using microcosting. See 
online supplemental table S14.
CS lifetime healthcare 
cost
80 423.37 – – Gamma Average additional lifetime healthcare 
costs attributable to CS based on cost 
estimate for cerebral palsy (estimate 
from 2000).22
CS lifetime health and 
social care cost
651 387.47 – – Gamma Average additional lifetime health and 
social costs attributable to CS based 
on cost estimate for cerebral palsy 
(estimate from 2000).22
For costs, high and low values are ±20% of baseline values with exception of syphilis screening cost where 
high and low values are ±50%.
*IUFD refers to the death of a baby in the uterus at ≥20 weeks gestation that is, stillbirth.
†Neonatal death refers to the death of a baby within the first 28 days after birth.
‡These probabilities refer to the final diagnosis after all diagnostic testing plus discussion with sexual health 
consultant if diagnostic tests result is positive for treponemal antibodies.
CS, congenital syphilis; EIA, enzyme immunoassay; SASS, Surveillance of Antenatal Syphilis Screening.
Table 1 Continued
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2. Incomplete uptake of the repeat screen—where the 
probability of having a second screen was 99.6%, in 
line with the current uptake of screening in England.
3. Increased syphilis incidence—varying incidence at 10 
intervals between the baseline and the high value used 
in sensitivity analysis (0.012%).
4. No late presentation to antenatal care—all women are 
screened twice in the repeat screening strategy.
5. 100% sensitivity and specificity of the syphilis screen-
ing process.
6. 100% specificity of the repeat screen (ie, no false pos-
itives).
7. Examining the per screen cost required to meet the 
standard National Institute for Health and Care 
Excellence (NICE) cost- effectiveness threshold of £20 
000–£30 000.21
In scenario analysis 1, the lifetime healthcare and social 
care costs for infants born with CS were considered. Since 
no data on the lifetime cost of CS were available, cerebral 
palsy (CP) was used as a proxy as it can also lead to a range 
of disabilities, vary hugely in severity, and may sometimes 
be a result of CS. The lifetime health and social care costs 
of CP were taken from a single Danish study22 adjusted to 
reflect UK life expectancy and gender split.
As EuroQol five- dimensions (EQ- 5D) data have not 
been reported for CS or CP, a utility of 0.74 for infants 
with CS relative to a score of 1.00 for infants born with 
no CS was used, adapted from a 2006 study of new- born 
screening strategies where 0.74 was used for infants 
with ‘mild developmental delay’.23 These utility values 
were used in a similar health economic model from the 
USA16 and were used to calculate QALYs. In the absence 
of data on changes to utility for infants born with CS, it 
was assumed that the difference in utility between infants 
born with CS and infants with no CS remained constant 
through childhood and adulthood.
Parental HRQoLs were not considered, as this would 
add complexity to the model. There are no published 
data on many of the utility scores for each of the preg-
nancy outcomes, for maternal syphilis diagnosis or 
receiving a false negative result. These would need to be 
based on uncertain estimates or from expert opinion, 
due to limited evidence on HRQoL.
The life expectancy of infants with CS was estimated as 
70 years, in line with the estimate for CP22 and in light 
of reports of CS diagnoses in a wide range of ages.24 The 
life expectancy of infants with no CS was estimated as 81 
years based on current UK data.25 All costs and utilities 
were discounted at 3.5%, in line with NICE guidelines 
for England.26 In DSA, discounting of utilities was varied 
from 0% to 6%.
Patient and public involvement
There was no patient or public involvement (PPI) in the 
design of the evaluation. A report outlining the model 
was reviewed by the UK NSC which has PPI representa-
tion and was made available for public consultation.
RESULTS
Base case analysis
The base case results indicate that in 1 year of screening 
pregnant women in the UK (n=725 891), the repeat 
screening strategy would result in 5.5 fewer cases of 
CS, 2 fewer cases of preterm delivery, 0.1 fewer cases of 
neonatal death (ie, one less neonatal death every 10 years 
on average), and 0.3 fewer cases of IUFD compared with 
the single screening strategy (table 2).
The healthcare costs would be £9 886 863 higher for 
the repeat screening strategy (£1 777 469 008 vs £1 787 
355 870, respectively, when total annual screening costs, 
treatment costs and delivery costs for all pregnant women 
screened were considered) with most of this increase (£9 
162 355) being a result of the additional screening costs 
(table 3).
The model calculated that 124 292 women would need 
to be rescreened in the third trimester to prevent one 
case of CS, 2.6 million to prevent one case of IUFD (ie, 
one case prevented approximately every 3.6 years if every 
pregnant woman was rescreened), and 5.5 million to 
prevent one case of neonatal death (ie, one case prevented 
approximately every 7.6 years if every pregnant woman 
was rescreened, table 4). It would cost an additional £1 
791 880 per case of CS prevented, £37 852 707 per case 
of IUFD prevented and £79 507 578 per neonatal death 
prevented. An additional 251 women need to receive 
treatment for syphilis to prevent one case of CS (table 4).
Sensitivity and scenario analyses
The DSA results indicated that even accounting for 
parameter uncertainty, the total cost of the repeat 
screening strategy was always higher than the cost of the 
single screening strategy (see online supplemental figure 
S2 for Tornado diagram). Total costs were most sensitive 
to changes in the per screen cost, but also to changes in 
the specificity of the screening process, the proportion 
of women first attending antenatal care before their 
third trimester, syphilis incidence and the cost of syphilis 
treatment (online supplemental figure S2). In the DSA 
examining the impact of clinical and cost parameters on 
the number of CS cases, the model was most sensitive to 
syphilis incidence during pregnancy and the probability 
of CS in infants born to women infected with syphilis 
during pregnancy who did not receive treatment (ie, 
were undiagnosed; see online supplemental figure S3). 
In all iterations in the 1000 PSA Monte Carlo simulations, 
the repeat screening strategy cost more than the single 
screening strategy and resulted in fewer cases of CS. The 
incremental cost and incremental cases of CS prevented 
are shown in online supplemental figure S4.
When lifetime costs and utilities were considered 
(scenario 1), the health and social care cost per addi-
tional QALY gained for the repeat screening strategy 
(ICER) was £120 494. In DSA, the ICER was £32 716 and 
£205 600, when discounting of utilities was 0% and 6%, 
respectively (see online supplemental table S15). Even if 
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a lower discounting rate were considered by NICE in the 
future, it is unlikely that 0% discounting would be used.
In further scenario analyses, reducing the uptake of 
repeat testing to 99.6% (in line with current uptake of 
the first screen, Scenario 2), including all women who 
attended antenatal care before their third trimester (ie, 
no late first screen, scenario 4), including 100% sensi-
tivity and specificity of the screening process (scenario 
5), or including no false positives in the second screen 
(scenario 6) had very little impact on the model outcomes, 
reducing the base case cost per CS case avoided by <10% 
(data not shown).
When the probability of becoming infected with syph-
ilis between screens was increased sevenfold to 0.00012 
(scenario 3), repeat screening resulted in 39 fewer cases 
of CS compared with single screening, 0.9 fewer neonatal 
deaths, 13 fewer preterm deliveries, and 1.8 fewer cases 
of IUFDs while the repeat strategy cost an additional £9 
638 476 (online supplemental tables S16 and S17). In this 
scenario, the cost per CS case prevented was £247 284 
(online supplemental table S18). Online supplemental 
table S19 in the online supplement presents the cost per 
case of CS avoided and the ICER when the probability 
of becoming infected with syphilis between screens is 
higher than baseline (at 10 intervals between 0.00003 and 
0.00012). As anticipated, with each increase in incidence, 
the repeat screening strategy resulted in more CS cases 
prevented and a lower cost per CS case prevented. When 
lifetime healthcare and social- care costs were considered, 
the ICER was £11 171 (below the £20–£30k threshold 
used by NICE), when syphilis incidence in pregnancy was 
0.004% and became cost saving at an incidence of 0.005% 
(1 in 100 000) or higher.
Scenario 7 examined the cost per screen needed to 
meet NICE ICER thresholds (at the current syphilis 
incidence) (see online supplemental table 20). The per 
screen cost would need to decrease from £13.36 to £6.46 
to take the ICER below £30k and £5.70 to take it below 
£20k when lifetime health and social care costs and utili-
ties of CS were considered.
DISCUSSION
We report on the cost- effectiveness of repeat universal 
syphilis antenatal screening in the UK. Our results 
indicate that this screening strategy would not be cost- 
effective in the current UK setting where the prevalence 
and incidence of syphilis among pregnant women is low. 
Although the repeat screening strategy is likely to result 
in fewer cases of CS, the number of cases prevented would 
be small, 5–6 a year, and would cost an additional £9.9 
million, equivalent to £1.8 million per case prevented. 
Most of the increase in cost is a result of the additional 
costs related to providing the second screen rather than 
treatment or delivery costs for women with syphilis.
The PSA and DSA indicated that the model results are 
robust to changes in the inputs. When lifetime health 
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(HRQoL) were considered (Scenario 1), the cost per 
QALY gained was £120 494 for the repeat screening 
strategy compared with the single screening strategy. This 
is well above the £20k–£30k cost per QALY threshold that 
NICE uses to assess interventions,21 and also exceeds the 
£100 000 threshold used to assess drugs/interventions for 
rare conditions (the threshold used when the interven-
tion results in <10 additional QALYs to an individual in 
their lifetime).27 For this analysis, costs and utilities were 
discounted by 3.5%, in line with NICE guidelines for 
England.26 When no discounting of utilities was assessed 
in DSA, the cost per QALY gained was £32 716, just above 
the £30k threshold.
Only two previous economic evaluations have assessed 
universal repeat syphilis screening in pregnancy 
compared with single screening in early pregnancy, both 
in the USA. Albright et al reported that repeat third- 
trimester screening would prevent 60 CS cases per 4 
million women costing US$419 842 per case avoided, 
concluding that repeat screening was not cost- effective.17 
Hersh et al found that repeat screening would prevent 41 
CS cases per 3.9 million women and result in total cost 
savings of US$52 million.16 Neither study accounted for 
late presentation to antenatal care—syphilis prevalence 
and incidence were considerably higher than in the UK 
as were healthcare costs.
It is important to note that changes to the screening 
strategy would not change the number of adverse preg-
nancy outcomes in women who decline screening, in 
women who present late to antenatal care and have one 
screen but no opportunity for a repeat screen, or in 
women who first present at the time of delivery, thereby 
missing the opportunity for any antenatal screening or 
treatment. For this reason, and because treatment for 
syphilis is not universally effective at preventing adverse 
pregnancy outcomes, it is likely that there would continue 
to be a very small number of infants born with CS each 
year irrespective of changes made to the screening 
strategy.
Strengths and weaknesses
This is the first health economic analysis to assess the costs 
and clinical benefits of a repeat screening strategy for 
syphilis compared with a single screen strategy within the 
UK setting. The input values in the model were based on 
the best available evidence from the published literature, 
Table 3 Base case short- term annual healthcare costs from model comparing universal repeat screening of syphilis in late 
















Estimate £1 777 469 008 £9 697 904 £535 434 £1 767 235 670
Lower 95% CI
Upper 95% CI
£1 769 393 140





£1 759 111 560
£1 768 490 710
Alternative: repeat screen
Estimate £1 787 355 870 £18 860 259 £970 254 £1 767 525 357
Lower 95% CI
Upper 95% CI
£1 779 322 118





£1 759 402 583
£1 768 782 187
Cost difference £9 886 863 £9 162 355 £434 820 £289 687
*Costs to the NHS in the UK for all 725 891 pregnant women screened. Costs are spilt into (1) antenatal screening costs, which includes 
sample collection and laboratory testing; (2) syphilis treatment within sexual health clinics and (3) perinatal costs, which includes the costs of 
delivery and neonatal care for all infants.
NHS, National Health Service.
Table 4 Requirements to prevent one outcome—from model comparing universal repeat screening of syphilis in late 











Congenital syphilis £1 791 880 124 294 251 249
Intrauterine fetal demise £37 852 707 2 625 664 5300 5251
Neonatal death £79 507 578 5 515 066 11 133 11 030
FP, false positive; TP, true positive.
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UK- specific surveillance data, NHS tariffs and published 
costs, and with input from experts in the field where 
data were lacking. These inputs were rigorously tested in 
sensitivity and scenario analyses to add confidence to the 
results, despite limited data in some areas.
There were sparse UK data available on pregnancy 
outcomes in women treated for syphilis or in infants born 
with CS. There are no published EQ- 5D scores for CS 
and a lack of evidence on changes to utility and health 
and social care costs over time for infants born with CS. 
We therefore used the additional lifetime cost of CP, esti-
mated in a study from Denmark,22 as a proxy for the life-
time cost of CS. As such, the primary focus of the analysis 
was the short- term costs and CS cases avoided since it was 
difficult to have confidence in the estimate used for life-
time CS cost or utility.
The model assumed that women could not become 
infected with syphilis between the repeat screen and 
delivery. As the incidence estimate relates to the full 
duration of pregnancy, this assumption would overes-
timate the number of women diagnosed and treated at 
the repeat screen, thereby overestimating the benefits 
of the repeat screen strategy. However, the number of 
women who become infected with syphilis during preg-
nancy is small and as such this would have little impact 
on the overall results. Since we do not know what repeat 
screening coverage would be, the model assumed 100% 
coverage, since all women in the model had already 
agreed to a first screen. This is optimistic, since it assumes 
continued engagement with antenatal services. However, 
scenario analysis 2 showed that even when uptake was 
<100% it would be unlikely to have much impact on the 
cost per CS case avoided.
It was also assumed that all women and neonates diag-
nosed with syphilis receive the appropriate full course 
of treatment and all infants born to women diagnosed 
with syphilis in pregnancy receive syphilis testing at birth. 
However, the SASS study13 found that in 2010–2011, not 
all women diagnosed with syphilis received complete 
treatment and inadequate paediatric follow- up was iden-
tified as an issue. Lack of treatment in these women and 
neonates is likely to make the repeat screening even less 
cost- effective.
Since there are no published estimates of the diag-
nostic accuracy (DA) of the syphilis screening process, 
accounting for the DA of laboratory assays and the diag-
nosis decision making by clinicians, average sensitivity 
and specificity of EIA assays used in UK laboratories were 
used.28 The DA values used here are considerably higher 
than those used in the US models,16 17 where a different 
testing algorithm is used29 and would, if anything, bias 
repeat screening results towards being more cost- effective.
Implications for clinicians and policy-makers
The number of CS cases was most sensitivity to changes 
in the syphilis incidence between screens. It may be cost- 
effective to repeat screen for a period of time where there 
is a known syphilis outbreak or if there are multiple cases 
of CS in a short period within the same geographical 
area in women who tested negative for syphilis at the first 
screen—as this would indicate a much higher syphilis 
incidence in pregnancy in that area.
Our model focused on the UK but is relevant to other 
European countries with similar syphilis prevalence and 
healthcare costs. Our analyses, using UK cost estimates, 
suggest that a universal second screen in late pregnancy 
could become cost- effective if the incidence of syphilis in 
pregnancy were to increase (to 5 per 100 000 pregnant 
women), indicating that in countries that have far higher 
syphilis prevalence than the UK, a second screen could 
be cost saving. For example, recent estimates suggest that 
the prevalence of syphilis in the WHO African region is 
more than 10- fold higher than in the WHO European 
Region.30 In such a high prevalence setting, combined 
with lower local healthcare costs, a second syphilis screen 
in late pregnancy could be cost- effective.
There could be some negative impact associated with 
repeat screening. A false positive result may lead to addi-
tional costs, unnecessary anxiety for mothers and their 
families, impact the mother’s relationships, possibly even 
damage their confidence in the screening programme, as 
well as lead to overtreatment. It is vital to minimise unnec-
essary use of antibiotics where possible given growing 
concerns around antimicrobial resistance and because 
there is some evidence that antibiotic use in pregnancy 
increases the risk of childhood epilepsy, obesity and 
asthma.31
Alternative approaches to reduce the number of CS 
cases and other adverse pregnancy outcomes could 
be more cost- effective and should be explored. These 
include better targeting of high- risk individuals and 
sexual health promotion in pregnancy. Furthermore, of 
the 20 CS cases in the UK since 2010, 11 had no record 
of the mother receiving antenatal screening. It remains 
unknown whether this was because testing was refused 
or due to very late/no first antenatal attendance.15 This 
highlights the need to ensure timely screening in preg-
nancy, particularly in women who present late who are 
already at increased risk of adverse pregnancy outcomes. 
Education for pregnant women around sexual health 
and STI prevention might be cost- effective and could be 
considered.
Unanswered questions and future research
Our model had a single disease focus. At present, 
however, pregnant women are screened for syphilis, HIV 
and hepatitis B. It would be useful to assess the poten-
tial cost- effectiveness of a repeat screen for all three 
infections since treatment for these infections during 
late pregnancy and/or at birth would reduce the risk of 
vertical transmission. Screening for all three infections 
may yield more benefits in terms of clinical outcomes and 
may make this strategy more cost- effective.
Furthermore, data collection including gestational 
week of first screen, coverage of repeat screen in high- 
risk women, pregnancy outcome for women treated for 
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syphilis, stage of infection in women diagnosed with 
syphilis and cost estimation for lifetime costs of being 
born with CS, would help inform future evaluations of 
screening strategies.
CONCLUSIONS
The results of this health economic analysis indicate that 
implementing universal repeat screening for syphilis in 
pregnancy is unlikely to be cost- effective in the current 
UK setting where the prevalence and incidence of syph-
ilis in pregnant women is low. Repeat screening could be 
considered in areas with a high syphilis incidence in preg-
nancy and may then be cost- effective, particularly if the 
cost per screen is low.
If syphilis prevalence continues to increase, the cost- 
effectiveness of the repeat screening strategy should be 
re- examined, highlighting the importance of continued 
monitoring of syphilis in pregnant women, screening 
uptake, CS cases and long- term follow- up.
Author affiliations
1Aquarius Population Health Ltd, London, UK
2UK National Screening Committee, Public Health England, London, UK
3UCL Institute for Global Health, University College London, London, UK
4Department of Paediatric Infectious Diseases & Immunology, Evelina London 
Children's Hospital, London, UK
5Department of Paediatrics, The Royal Children's Hospital Melbourne, Melbourne, 
Victoria, Australia
6School of Veterinary Science, University of Bristol, Bristol, UK
Twitter Susie Huntington @AquariusPH, Katy Turner @katymeturner and Elisabeth 
Adams @aquariusph
Acknowledgements We would also like to thank the following people for their 
contributions to this work: Nicola Bowers, Helen Fifer, Lyn Hutchison, Margaret 
Kingston, Anne Mackie, Paddy McMaster, Catherine Peckham, Ian Simms, Judith 
Timms and Sharon Webb.
Contributors The model structure was developed by SH, with input from GW, FS 
and JM. The final model structure was informed by input from JM, HB, MT, IA, KT 
and EA. SH developed the model parameters with input from MT, IA, GW, HB, FS, 
JM and KT. SH drafted the paper. All authors contributed to the interpretation of the 
results and contributed to the contents of the paper. All authors have approved the 
final submitted version.
Funding Award/Grant number is not applicable.
Competing interests SH, GW and EA work at Aquarius Population Health and have 
received consultancy fees from the following companies on projects related to STIs: 
Abbott, Cepheid, Binx Health, Hologic and St. Georges University of London. IA, KT 
and MT were funded as consultants on the project through Aquarius Population 
Health. MT has received support from Cepheid for conference attendance. KT is in 
receipt of funding to University of Bristol from GlaxoSmithKline for work unrelated 
to this work.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the 
article or uploaded as online supplemental information.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Susie Huntington http:// orcid. org/ 0000- 0002- 2854- 7441
Georgie Weston http:// orcid. org/ 0000- 0003- 3019- 7150
Farah Seedat http:// orcid. org/ 0000- 0002- 3563- 7875
John Marshall http:// orcid. org/ 0000- 0002- 6239- 774X
Heather Bailey http:// orcid. org/ 0000- 0003- 3266- 1041
Katy Turner http:// orcid. org/ 0000- 0002- 8152- 6017
Elisabeth Adams http:// orcid. org/ 0000- 0002- 4222- 9394
REFERENCES
 1 Public Health England. Sexually transmitted infections (STIs): Annual 
Data Tables 2014-2018, 2019. Available: https://www. gov. uk/ 
government/ statistics/ sexually- transmitted- infections- stis- annual- 
data- tables
 2 Ricci JM, Fojaco RM, O'Sullivan MJ. Congenital syphilis: the 
University of Miami/Jackson Memorial medical center experience, 
1986-1988. Obstet Gynecol 1989;74:687–93.
 3 Sheffield JS, Sánchez PJ, Morris G, et al. Congenital syphilis after 
maternal treatment for syphilis during pregnancy. Am J Obstet 
Gynecol 2002;186:569–73.
 4 Gomez GB, Kamb ML, Newman LM, et al. Untreated maternal 
syphilis and adverse outcomes of pregnancy: a systematic review 
and meta- analysis. Bull World Health Organ 2013;91:217–26.
 5 De Santis M, De Luca C, Mappa I, et al. Syphilis infection during 
pregnancy: fetal risks and clinical management. Infect Dis Obstet 
Gynecol 2012;2012:1–5.
 6 Mwaniki MK, Atieno M, Lawn JE, et al. Long- Term 
neurodevelopmental outcomes after intrauterine and neonatal insults: 
a systematic review. The Lancet 2012;379:445–52.
 7 Arnold SR, Ford- Jones EL. Congenital syphilis: a guide to diagnosis 
and management. Paediatr Child Health 2000;5:463–9.
 8 NHS Digital. NHS Maternity Statistics, England 2017-18, 2018. 
Available: https:// digital. nhs. uk/ data- and- information/ publications/ 
statistical/ nhs- maternity- statistics/ 2017- 18 [Accessed 19 Jun 2019].
 9 PHE and NHS. NHS Infectious Diseases in Pregnancy Screening 
Programme Screening Standards Data Report 1 April 2016 to 31 
March 2017, 2019. Available: https://www. gov. uk/ government/ 
publications/ infectious- diseases- in- pregnancy- screening- standards- 
data- report [Accessed 21 May 2019].
 10 Public Health Agency, Belfast. Sexually transmitted infection 
surveillance in Northern Ireland. An analysis of data for the calendar 
year 2016, 2017. Available: https://www. gov. uk/ government/ 
statistics/ sexually- transmitted- infections- stis- annual- data- tables
 11 Public Health England. NHS Infectious Diseases in Pregnancy 
Screening Programme Handbook 2016 to 2017, 2016. Available: 
https://www. gov. uk/ government/ publications/ infectious- diseases- in- 
pregnancy- screening- programme- handbook
 12 Public Health England. Screening tests for you and your baby. 
Important information about the screening choices you will have 
during and after your pregnancy. NHS booklet, 2020. Available: 
https:// assets. publishing. service. gov. uk/ government/ uploads/ 
system/ uploads/ attachment_ data/ file/ 865122/ Screening_ tests_ for_ 
you_ and_ your_ baby_ information_ leaflet. pdf
 13 Townsend CL, Francis K, Peckham CS, et al. Syphilis screening in 
pregnancy in the United Kingdom, 2010-2011: a national surveillance 
study. BJOG: Int J Obstet Gy 2017;124:79–86.
 14 World Health Organization. Global guidance on criteria and 
processes for validation: elimination of mother- to- child transmission 
(EMTCT) of HIV and syphilis. Geneva World Health Organization; 
2013. https://www. who. int/ reproductivehealth/ publications/ emtct- 
hiv- syphilis/ en/
 15 Furegato M, Fifer H, Mohammed H, et al. Factors associated with 
four atypical cases of congenital syphilis in England, 2016 to 2017: 
an ecological analysis. 2017;22.
 16 Hersh AR, Megli CJ, Caughey AB. Repeat screening for syphilis 
in the third trimester of pregnancy: a cost- effectiveness analysis. 
Obstet Gynecol 2018;132:699–707.
 on F









pen: first published as 10.1136/bm






11Huntington S, et al. BMJ Open 2020;10:e038505. doi:10.1136/bmjopen-2020-038505
Open access
 17 Albright CM, Emerson JB, Werner EF, et al. Third- Trimester prenatal 
syphilis screening: a cost- effectiveness analysis. Obstet Gynecol 
2015;126:479–85.
 18 Qin J, Yang T, Xiao S, et al. Reported estimates of adverse pregnancy 
outcomes among women with and without syphilis: a systematic 
review and meta- analysis. PLoS One 2014;9:e102203.
 19 XE Currency Converter. Available: https://www. xe. com/
 20 Curtis L, Burns A. Unit costs of health and social care 2018, personal 
social services research unit, University of Kent, Canterbury, 2018. 
Available: https://www. pssru. ac. uk/ project- pages/ unit- costs/ unit- 
costs- 2018/
 21 National Institute for Clinical Excellence. Guide to the methods of 
technology appraisal 2013, 2013. Available: https://www. nice. org. 
uk/ process/ pmg9/ resources/ guide- to- the- methods- of- technology- 
appraisal- 2013- pdf- 2007975843781
 22 Kruse M, Michelsen SI, Flachs EM, et al. Lifetime costs of cerebral 
palsy. Dev Med Child Neurol 2009;51:622–8.
 23 Carroll AE, Downs SM. Comprehensive cost- utility analysis of 
newborn screening strategies. Pediatrics 2006;117:S287–95.
 24 Probst LE, Wilkinson J, Nichols BD. Diagnosis of congenital syphilis 
in adults presenting with interstitial keratitis. Can J Ophthalmol 
1994;29:77–80.
 25 Office for National Statistics. National Life Tables, UK: 2016 - 2018, 
2019. Available: https://www. ons. gov. uk/ peop lepo pula tion andc 
ommunity/ birt hsde aths andm arriages/ lifeexpectancies/ bulletins/ nati 
onal life tabl esun ited kingdom/ 2016to2018 [Accessed 1 Oct 2019].
 26 National Institute for Health and Care Excellence. How should NICE 
assess future costs and health benefits. NICE citizens Council 
meeting, 2020. Available: https://www. nice. org. uk/ Media/ Default/ 
Get- involved/ Citizens- Council/ Reports/ CCRe port 15Di scou nting. 
pdf
 27 Powell T, O’Donnell M. House of commons debate pack. NICE 
appraisals of rare diseases, 2019. Available: http:// researchbriefings. 
files. parliament. uk/ documents/ CDP- 2019- 0022/ CDP- 2019- 0022. pdf
 28 Public Health England. Data on EIA assays used in UK supplied by 
lead microbiologist for bacterial STIs at the National infection service; 
2019.
 29 Morshed MG, Singh AE. Recent trends in the serologic diagnosis of 
syphilis. Clin Vaccine Immunol 2015;22:137–47.
 30 Rowley J, Vander Hoorn S, Korenromp E, et al. Chlamydia, 
gonorrhoea, trichomoniasis and syphilis: global prevalence 
and incidence estimates, 2016. Bull World Health Organ 
2019;97:548–62.
 31 Kuperman AA, Koren O. Antibiotic use during pregnancy: how bad is 
it? BMC Med 2016;14.
 32 Shiber L, Todia WJ. Cost and clinical utility of repeated syphilis 
screening in the third trimester in a high- risk population. Am J Obstet 
Gynecol 2014;210:267.e1–267.e5.
 33 Pathway Analytics. Integrated Sexual Health Tariff - London ISHT 
2017/2018. Available: https://www. pathwayanalytics. com/
 34 Campbell HE, Kurinczuk JJ, Heazell A, et al. Healthcare and wider 
societal implications of stillbirth: a population- based cost- of- illness 
study. BJOG 2018;125:108–17.
 35 Khan KA, Petrou S, Dritsaki M, et al. Economic costs associated with 
moderate and late preterm birth: a prospective population- based 
study. BJOG: Int J Obstet Gy 2015;122:1495–505.
 on F









pen: first published as 10.1136/bm
jopen-2020-038505 on 19 N
ovem
ber 2020. D
ow
nloaded from
 
